A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus

Trial Profile

A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Serlopitant (Primary)
  • Indications Pruritus
  • Focus Therapeutic Use
  • Sponsors Tigercat Pharma
  • Most Recent Events

    • 20 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Dec 2014 Results published in a Tigercat Pharma media release.
    • 17 Dec 2014 Primary endpoint has been met (percent change in Visual Analogue Scale itch score from baseline, comparing drug to placebo), according to a Tigercat Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top